222 related articles for article (PubMed ID: 36572182)
1. Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.
Kritikos V; Harvey ES; Stevens S; Katelaris CH; Langton D; Rimmer J; Farah CS; Gillman A; Hew M; Radhakrishna N; Thomas D; Gibson PG;
J Allergy Clin Immunol Pract; 2023 Mar; 11(3):885-895.e13. PubMed ID: 36572182
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study.
Bravo-Gutiérrez FJ; Miralles-López JC; Valverde-Molina J; Alemany Francés ML; Andújar-Espinosa R; Castilla-Martínez M; Avilés-Inglés MJ; Mora-González A; Pajarón-Fernández MJ; Cabrejos-Perotti S; Meseguer-Arce J; Flores Martín I; Pérez-Fernández V;
Int Arch Allergy Immunol; 2024; 185(3):253-259. PubMed ID: 38035559
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities.
Casale T; Molfino NA; Silver J; Bogart M; Packnett E; McMorrow D; Wu J; Hahn B
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):354-362.e2. PubMed ID: 34038773
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis.
Liu MC; Bagnasco D; Matucci A; Pilette C; Price RG; Maxwell AC; Alfonso-Cristancho R; Jakes RW; Lee JK; Howarth P
J Allergy Clin Immunol Pract; 2023 Dec; 11(12):3650-3661.e3. PubMed ID: 37507070
[TBL] [Abstract][Full Text] [Related]
5. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
[TBL] [Abstract][Full Text] [Related]
6. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
Comberiati P; McCormack K; Malka-Rais J; Spahn JD
J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
[TBL] [Abstract][Full Text] [Related]
7. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities.
Crimi C; Campisi R; Cacopardo G; Intravaia R; Nolasco S; Porto M; Pelaia C; Crimi N
World Allergy Organ J; 2020 Sep; 13(9):100462. PubMed ID: 32994855
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab effectiveness and identification of super-responders in severe asthma.
Harvey ES; Langton D; Katelaris C; Stevens S; Farah CS; Gillman A; Harrington J; Hew M; Kritikos V; Radhakrishna N; Bardin P; Peters M; Reynolds PN; Upham JW; Baraket M; Bowler S; Bowden J; Chien J; Chung LP; Grainge C; Jenkins C; Katsoulotos GP; Lee J; McDonald VM; Reddel HK; Rimmer J; Wark PAB; Gibson PG
Eur Respir J; 2020 May; 55(5):. PubMed ID: 32139455
[TBL] [Abstract][Full Text] [Related]
9. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
10. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study.
Pavord I; Gardiner F; Heaney LG; Domingo C; Price RG; Pullan A; Oppenheimer J; Brusselle G; Nagase H; Chupp G; Pizzichini E; Bañas-Conejero D; Howarth P
Front Immunol; 2023; 14():1150162. PubMed ID: 37122713
[TBL] [Abstract][Full Text] [Related]
11. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
Gibson PG; Prazma CM; Chupp GL; Bradford ES; Forshag M; Mallett SA; Yancey SW; Smith SG; Bel EH
Respir Res; 2021 Jun; 22(1):171. PubMed ID: 34098955
[TBL] [Abstract][Full Text] [Related]
13. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of mepolizumab in patients with severe eosinophilic asthma: In a real life study].
Bulut İ; Yegin Katran Z; Yavuz D; Yıldız AB; Yakut T; Örçen C; Mersin SS
Tuberk Toraks; 2023 Jun; 71(2):148-155. PubMed ID: 37345397
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.
Özdel Öztürk B; Yavuz Z; Eraslan D; Mungan D; Demirel YS; Aydın Ö; Sin BA; Bavbek S
Int Arch Allergy Immunol; 2022; 183(5):526-538. PubMed ID: 34915496
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.
Fyles F; Nuttall A; Joplin H; Burhan H
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2715-2723. PubMed ID: 37245734
[TBL] [Abstract][Full Text] [Related]
18. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
Bachert C; Sousa AR; Han JK; Schlosser RJ; Sowerby LJ; Hopkins C; Maspero JF; Smith SG; Kante O; Karidi-Andrioti DE; Mayer B; Chan RH; Yancey SW; Chaker AM
J Allergy Clin Immunol; 2022 May; 149(5):1711-1721.e6. PubMed ID: 35007624
[TBL] [Abstract][Full Text] [Related]
19. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.
Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG;
Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602
[TBL] [Abstract][Full Text] [Related]
20. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
